REMUS PHARMACEUTICALS Q2 FY27 CONCALL: EXPECTS STRONGER H2 GROWTH & SP GLOBAL MARGIN RECOVERY; TARGETS 25–30% B2C REVENUE CONTRIBUTION, 5–7% LONG-TERM SP GLOBAL MARGIN & PERU COMMERCIALISATION IN H2 FY27